Navigation Links
Avillion LLP Receives Initial Funding From Abingworth and Clarus

LONDON, January 28, 2013 /PRNewswire/ --

Avillion LLP, which focuses on clinical co-development of therapeutics, today announced that it has received initial funding from Abingworth LLP and Clarus Ventures.

Avillion, based in London, UK, is partnering with pharmaceutical and biotechnology companies to co-developand finance latestage therapeutics. The company will use its clinical development and regulatory expertise to obtain global approvalsfor a broad range of drugs and biologics.

Lewis Cameron , theCEO of Avillion, commented: "Avillion offers pharma and biotech companies a compelling option to partner late stage drug approval projects globally. We have an experienced team focused on global drug development and approval, with the capability to optimise CRO management."

The management team is led by Lewis Cameron (CEO), who has held senior executive positions in CRO companies,including Chiltern International, Clearstone and LabCorp. Dr Allison Jeynes-Ellis (CMO) has over 20 years experience running clinical trials for pharmaceutical companies,including Wyeth and BMS, and has been extensively involved in health technology appraisals across various countries. Graham Higson (VP, Regulatory) has three decades of regulatory experience, including 5 years as the global head of regulatory affairs at AstraZeneca. John Bradshaw (CFO) provides financial services to life sciences companies and has extensive experience in dealing with complex accounting and finance issues relevant to the pharmaceutical industry.

Genghis Lloyd-Harris , a partner at Abingworth, said: "We founded Avillion and incubated the company in our London office. The Avillion team has exceptionally broad and deep experience in CRO management, drug development and regulatory approval. Avillion provides an excellent choice for co-developing phase III drugs and biologics in the US and Europe."

Notes for Editors

About Abingworth

Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sector. The company invests at all stages of development including early and late-stage venture financing, growth equity and public companies.

Founded in 1973, Abingworth has a lengthy track record of backing market leading companies. Abingworth has a specialist team of 19 professionals with a broad range of skill sets and access to an extensive network of industry contacts. Abingworth has funds under management of over $1.25 billion and offices in London, Menlo Park (California) and Boston.

About Clarus

Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment and operating professionals. The investment team has extensive and broad backgrounds in research and development, commercialization, business development and operations management, which enabled Clarus to establish a long history of success in creating value across multiple disciplines within the healthcare-investing universe. The deep domain expertise of the Clarus team allows us to employ a hands-on philosophy of providing value enhanced leadership and guidance in working with our management teams in both the biopharmaceutical and medical device arenas. Clarus is presently managing $1.2 billion. The firm invests globally out of its offices in Cambridge, MA and South San Francisco, CA.

For Avillion
Lewis Cameron
Tel: +44(0)207470-2458

For Abingworth
Genghis Lloyd-Harris
Tel: +44(0)20-7534-1500

For Clarus
Kurt Wheeler
Managing Director
Tel: +1-(650)-238-5055

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. St. Mark’s School Receives $4.8 Million Gift from Tech Pioneer Graduate
2. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
3. RiboMed Receives Three Additional Patents for Disease Diagnostics Methods
4. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
5. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
6. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
7. Ceres Receives $3.5 million from USAID for Trait Stacks
8. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
9. Hertz Fellow, Grant I. Gillary, Receives Hertz Foundation-George Lerman Fellowship
10. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
11. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... SUNNYVALE, Calif. , Nov. 24, 2015 ... executives will be speaking at the following conference, and ... New York, NY      Tuesday, December 1, ... New York, NY      Tuesday, December 1, ...      Piper Jaffray Healthcare Conference, New York, NY ...
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions ... in five states to develop and pitch their BIG ideas to improve health and ... are competing for votes to win the title of SAP's Teen Innovator, an all-expenses ...
Breaking Biology Technology:
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
Breaking Biology News(10 mins):